Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 17Cyclophosphamide 8zanubrutinib 7Bendamustine Hydrochloride 7obinutuzumab 6Lenalidomide 6venetoclax 5blinatumomab 5acalabrutinib 5Vincristine 5fludarabine 4Prednisone 4Methotrexate 4Doxorubicin 4Cytarabine 4Brentuximab Vedotin 4ibrutinib 3Specimen Handling 3Dexamethasone 3Crizotinib 3tisagenlecleucel 2tafasitamab 2polatuzumab vedotin 2pirtobrutinib 2pegaspargase 2idelalisib 2duvelisib 2axicabtagene ciloleucel 2avapritinib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × tafasitamab × Lymphoid × Clear all
NCT04680052 2025-12-22

InMIND

Incyte Corporation

Phase 3 Active not recruiting
654 enrolled 40 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02399085 2023-10-23

L-MIND

MorphoSys AG

Phase 2 Completed
81 enrolled 23 charts 1 FDA
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡